UK Evacuates Ebola-Infected British Doctor From DR Congo for Specialist Treatment

The United Kingdom has evacuated a British medical doctor who tested positive for Ebola virus disease while treating patients in the Democratic Republic of the Congo (DRC).

The doctor, whose identity has not been disclosed, was flown to the UK on Thursday to receive specialist medical attention following confirmation of the infection.

The UK Department of Health and Social Care disclosed this in a statement titled, “UK Citizen Returned from DRC for Specialist Ebola Care,” published on the government’s official website.

According to the statement, the evacuation was jointly coordinated by the British and Congolese governments, alongside international health partners, with strict infection prevention and control measures observed throughout the operation.

The doctor is currently receiving treatment at a high-level isolation unit at the Royal Free Hospital in London, a specialised facility designed to manage highly infectious diseases.

The statement said the hospital’s medical team had activated strict isolation procedures to prevent any contact between the patient and members of the public.

It added that healthcare workers attending to the doctor were equipped with appropriate personal protective equipment and were following established safety protocols to prevent further transmission.

The Deputy Director of All Hazards Public Health Response at the UK Health Security Agency (UKHSA), Dr Renu Bindra, said the agency and the National Health Service had established procedures to contain the infection and minimise the risk of further transmission.

She assured the public that the risk of the disease spreading to the wider population remained low.

Sky News reported that the Royal Free Hospital had previously treated patients suffering from Lassa fever, Ebola and Crimean-Congo haemorrhagic fever.

The latest incident is reportedly the first involving a British national connected to the ongoing Ebola outbreak, although several European nationals from other countries have contracted the disease in recent months.

According to the UK Health Security Agency, only four Ebola cases have been confirmed in the United Kingdom since 1976.

Three of those cases involved healthcare workers who participated in the response to the West African Ebola outbreak between 2014 and 2015.

Nigeria Monitors Contacts Following Imported Ebola Case

Meanwhile, Nigeria is continuing surveillance and contact-tracing activities following the confirmation of an imported Ebola case in the country in October 2026.

The Federal Government confirmed on October 20 that laboratory tests detected the Bundibugyo strain of Ebola in a woman who travelled to Nigeria from Uganda.

The World Health Organisation (WHO) said the patient developed symptoms on October 7, four days after arriving in Nigeria, before seeking medical attention at a private healthcare facility in Abuja on October 11.

Laboratory confirmation on October 20 made Nigeria the fifth country to report the virus since the outbreak was declared in the Democratic Republic of the Congo on May 15, 2026.

The infected woman was subsequently evacuated to Switzerland on October 26 for further medical treatment, alongside her husband, who was identified as a close contact.

Two additional suspected Ebola cases detected in Yola, Adamawa State, were later ruled out after two rounds of laboratory testing, reducing concerns about a possible spread of the infection to Nigeria’s North-East region.

The Nigeria Centre for Disease Control and Prevention (NCDC) said 62 contacts identified following the confirmation of the imported case were expected to complete their monitoring period by November 13, 2026.

The agency added that contact tracing and surveillance operations were ongoing, while additional contact tracers had been identified and trained to strengthen the country’s response.

WHO Approves Trials of Two New Ebola Vaccines

In another development, the World Health Organisation on November 4 approved clinical trials of two experimental vaccines developed specifically against the Bundibugyo strain of the Ebola virus.

The vaccines are ChAdOx1 BDBV, developed by the University of Oxford in collaboration with the Serum Institute of India, and mRNA-1469, developed by Moderna.

The approval is expected to support efforts by health authorities and medical researchers to develop effective protection against the strain responsible for the current outbreak.

The ongoing epidemic has reportedly claimed more than 5,300 lives, highlighting the urgent need for effective vaccines, improved treatment options and stronger international cooperation to contain the disease.

Join us on our WhatsApp Platform @KOIKIMEDIA NEWS YOUR PAGE

Koikimedia Bringing the World 🌎 Closer to Your Doorstep